Drug intelligence / Profile preview

ENX-104

Development stage: Phase 1
Lead developer: Engrail Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ENX-104 is an investigational small molecule being developed by Engrail Therapeutics for the treatment of major depressive disorder with anhedonia. Clinical studies are evaluating its safety, tolerability, pharmacokinetics, pharmacodynamics, and its ability to occupy D2/D3 dopamine receptors.

Targets

DRD3 (Dopamine receptor D3)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on ENX-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENX-104.

Explore the full profile